From the Journals
Clinical Guidelines

AGA issues updated guidance on HDV management

An AGA panel recommended universal HDV screening for all patients with chronic HBV infection.

Share

7 Key Takeaways

  • 1

    AGA guidelines focus on HDV management related to HBV infection.

  • 2

    Significant health risks include cirrhosis and liver-related mortality.

  • 3

    Universal screening for HDV in chronic HBV patients is recommended.

  • 4

    Pegylated interferon-alpha is currently the only approved treatment in the U.S.

  • 5

    New therapies are under trial, with potential for improved outcomes.

  • 6

    Screening rates among high-risk populations remain low.

  • 7

    Patients with HDV should undergo surveillance for liver cancer.

Original Source(s)

AGA issues updated guidance on HDV management

An AGA panel recommended universal HDV screening for all patients with chronic HBV infection.

  • by Amy Pfeiffer

  • November 6, 2025

  • 3 min

Related Content

Sarcopenia, thrombosis, and renal dysfunction dominate cirrhosis complication updates

New diagnostic approaches and treatment controversies emerge for managing advanced liver disease complications.

Open vs robotic liver resections, study results

Complication rates and hospital stays were analyzed across both surgical groups.

Zinc: Missing Link in HE Management?

Study reveals stark survival contrast: cirrhotic patients with normal zinc levels showed 86% survival rate versus significantly poorer outcomes in zinc-deficient patients (35.56 ± 11.65 mcg/dL, P<.0001), suggesting a potentially modifiable risk factor in hepatic encephalopathy management.